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Introduction
Calcified aortic stenosis is the most severe form of aortic 
valve disease and it is characterized by fibrocalcic remod-
eling. This remodeling process begins with a deposition of 
lipoproteins and chronic inflammation, resulting in osteo-
genic differentiation of valvular interstitial cells and active 
calcification of the layers [1, 2]. Despite similarities with 
the atherosclerotic process, no pharmacological treatment 
slowed the progression of the aortic stenosis.  Large-scale 
epidemiological studies have shown an annual incidence of 
calcific aortic stenosis in the range of 0.36 and 0.37 per 1000 
hospital-treated patients [3, 4]. In the general population, 
the incidence is higher (4.9 per 1000) when calculated on 
the basis of systematic echocardiographic examination. The 
prevalence of calcific aortic stenosis is estimated at 0.4% in 
the general population and between 1.3 and 1.7% in patients 
over 65 in developed countries [5-7]. The prevalence of cal-
cified aortic stenosis increases significantly after age of 65 
and it reaches its severe form of 3.4% after the age of 75, 
with 75% of symptomatic patients [8]. The natural course 
of severe symptomatic calcific aortic stenosis is particular-
ly dark, as shown by the 5-year mortality rate of 60% after 
the initial hospitalization. Mortality is increased in cases of 
heart failure or in octogenarians with comorbidities [9, 10]. 
The reliability of the epidemiological data of valvulopathy 
has important implications for the planning of therapeutic 
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Abstract
Background: The presence of aortic narrowing is common in the elderly and the prognosis is very poor in symptomatic patients. Prior to the era of 
percutaneous treatment of aortic stenosis, surgical aortic valve replacement (SAVR) was considered the “gold standard” of symptomatic aortic stenosis 
treatment. However, the records have shown that about 40% of patients at that time were not operated due to their age and their cardiac and non-cardiac 
comorbidities. The subsequent work was the implantation of aortic valve by transfemoral approach – transcatheter aortic valve implantation (TAVI). 
Several studies have acknowledged the place of aortic valvuloplasty which has become the reference technique for patients with contraindications or 
high surgical risk and even recently appeared as at least equivalent to, or even superior to, the surgery in patients at intermediate risk.  This development 
was accompanied by a renewed interest in aortic valvuloplasty, a TAVI that cannot reasonably be executed at first attempt in some patients.  In Europe, 
where this technique was born, the great experience that has been gained has led to a gradual simplification of the procedure. The purpose of this article 
is to describe the state of the art of TAVI and to discuss its future.
Conclusions: The aortic stenosis disease affects a large scale of people across the globe. The appearance of a new treatment method TAVI opens new 
era of treatment of this disease. The new TAVI method is a less invasive procedure than an open heart surgery and can be used in almost all the cases of 
patients with an aortic stenosis. 
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resources. The number of patients with aortic stenosis is ex-
pected to triple in the next 50 years [11-13].
History of transcatheter aortic valve implantation 
(TAVI)
The development of TAVI has been a long odyssey since 
the birth of the concept in the early 90s. The history began in 
1985 in Rouen with the introduction of the aortic dilatation 
balloon by Alain Criber. After considerable international 
interest in this technique, its limitations, particularly early 
valvular restenosis, led to the development of the “percuta-
neous aortic valve” concept. Faced with the absence of any 
industrial support, a start-up, “Percutaneous Valve Tech-
nologies”, was created which allowed the development and 
testing on animals of the first balloon-expandable dentures 
in 2000, before the first human implantation took place at 
the University Hospital Center on 16 April 2002 in Rouen 
[14]. The 2004 acquisition of this start-up by Edwards Life-
sciences was the starting point for significant technological 
improvements and increasing interest in TAVI, while two 
years later a competing self-expandable prosthesis was in-
troduced the Medtronic Core Valve. Multiple controlled 
registers and studies with these two prostheses have resulted 
in the extraordinary expansion of the TAVI that we know 
today, with inclusion in the European and American recom-
mendations since 2012 and a gradual and recently validated 
expansion of indications to patients with less risk [15]. Pre-
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TAVI Patient Assessment and selection is a key step in the 
implementation of a TAVI and should involve a multidis-
ciplinary team of cardiologists, imaging specialists, cardiac 
surgeons and geriatricians if needed or other specialists 
[16-21]. The investigations prior to TAVI should include: 
Echocardiography to confirm the severity of aortic stenosis, 
analyze aortic valve and ascending aortic morphology, size 
and function of the left ventricle to rule out dynamic ven-
tricular obstruction and evaluate the mitral valve; coronary 
angiography to determine revascularization options. The 
multi-cut coronary computer tomography (CT) is essential 
to the therapeutic decision, especially for the selection of the 
best approach in terms of vessel size, tortuosity and calcifi-
cation. When the indication of a TAVI is retained, a scan of 
the arteries is performed from the ascending thoracic aorta 
to the arteries of the lower limbs [22]. 
For the femoral approach, the ratio of the outer diameter 
of the vest to the minimum diameter of the vessel should be 
less than 1.1 in the absence of calcification. When the femo-
ral approach is not feasible, the scanner can make it possible 
to evaluate the feasibility of another pathway (transcarotide, 
transaortic, subclavian or transapical).
Transfemoral approach after the initial approach com-
bining a surgical and percutaneous approach is the approach 
currently entirely percutaneous. This is often the preferred 
approach because it offers the largest arterial diameters and 
has a lower rate of complications. 
Left subclavian / transaxillary approach: it allows TAVI 
with the CoreValve prosthesis in patients who cannot ben-
efit from a femoral approach, without requiring thoracoto-
my. Nevertheless, surgical exposure is required, with a pro-
cedure frequently performed under general anesthesia.
Transapical approach: it allows a direct anterograde ac-
cess via the tip of the VG, without passing through the aorta. 
This is a surgical approach that requires a left anterolateral 
intercostal incision, under general anesthesia. It is associ-
ated with higher mortality compared to the transfemoral 
route.
Transaortic approach: this approach consists of a mini-
sternotomy at the level of the ascending aorta, under gener-
al anesthesia. The aortic puncture site and the thoracic wall 
are surgically sutured at the end of the procedure. Other 
approaches have been developed more recently, such as the 
transcarotid approach or the brachiocephalic arterial trunk 
(fig. 1) [23-26]. 
Fig 1.  Different approach of TAVI.
In addition, in terms of calibration and selection of the 
appropriate valve type, CT has become the method of choice 
for assessing horizontal and ascending aorta, Valsalva sinus 
size, diameter and shape of the aortic annulus, the volume 
of calcifications, the bi- or tricuspid nature of the valve, the 
distance between the valvular ring and the ostium of the 
coronaries, the presence of a septal margin and possible cal-
cifications in the flush chamber. These explorations make it 
possible to choose the most appropriate calibers and types 
of valve and the best incidence for the positioning of the 
prosthesis. For patients with coronary disease and severe 
aortic stenosis, the strategy is most likely to allow complete 
vascularization. 
Patients treated with TAVI should be evaluated on a 
case-by-case basis by the multidisciplinary team, in the 
extent and complexity of the coronary lesions, the risk of 
myocardial infarct (risk of myocardial ischemia) and the 
potential complexity of the angioplasty, as well as the pres-
ence of any comorbidities. It should be emphasized that the 
recently published European Society of Cardiology (ESC) 
recommendations on myocardial revascularization advo-
cate angioplasty in patients with TAVI-treated coronary 
artery disease who have a stenosis greater than 70% in the 
proximal coronary segments [27-29]. 
The angioplasty and TAVI performed separately, or the 
two procedures performed concomitantly are strategies 
considered acceptable with respective advantages and dis-
advantages that must be carefully considered on a case-by-
case basis.
Technique of prosthesis implantation
Long considered to be at high risk of complications, per-
cutaneous aortic valvuloplasty has become a relatively sim-
ple act of interventional cardiology, well tolerated, requiring 
only local anesthesia and short hospitalization.
When the transfemoral route is chosen, a “crossover” 
technique (involving a wire placed in the contralateral artery 
to allow delivery of a balloon or stent to treat the access 
vessel in case of injury) is usually performed to “protect” the 
artery in case of vascular complication [30].
A temporary pacing wire (TPW) is positioned in the 
right ventricle via the jugular or femoral vein and may 
be required during balloon aortic valvuloplasty (BAV), 
implantation of the TAVI prosthesis, post-dilatation or if 
the patient develops significant conduction disturbance 
following valve deployment.
The aortic valve is usually crossed with the aid of a Judkins 
right 4 (JR4) or Amplatz left 1 (AL1) diagnostic catheter 
and a soft straight-tipped wire. This is then exchanged for a 
stiffer wire taking care to ensure that this is free of the mitral 
valve apparatus. Originally, wires (e.g., Amplatz Super Stiff™, 
Boston Scientific, Marlborough, MA, USA) were manually 
shaped to create a curve at the end to reduce the risk of 
ventricular injury during valve deployment. However, 
dedicated pre-shaped wires (e.g., the Safari™ pre-shaped 
TAVI guidewire; Boston Scientific)) have more recently been 
developed that have better memory (and therefore maintain 
their shape) to further reduce the risk of ventricular injury 
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(fig. 2). Stiffer wires, including the Lunderquist® Extra Stiff 
wire (Cook Medical, Bloomington, IN, USA) or the Back-
up Meier™ guidewire (Boston Scientific), may be used when 
greater support is required to deliver the TAVI device (e.g., 
in the setting of severe aortic tortuosity).
The aortic valve is initially crossed with a soft-tipped 
straight wire with the aid of an Amplatz left 1 catheter (fig. 2 
A). Once the valve is crossed (fig 2 B), the wire is exchanged 
for a stiff wire with a curved tip (white arrow) to minimise 
ventricular injury (fig. 2 C) over which the TAVI device is 
then advanced.
Transcatheter valves are positioned prior to deployment 
with the aid of aortography, fluoroscopy and, in some in-
stances, transoesophageal echocardiographic guidance. 
Balloon expandable valves require rapid ventricular pacing 
(180-220 beats per minute) for deployment to reduce car-
diac output and avoid inaccurate valve implantation [31]. 
Other devices may not routinely require ventricular pacing, 
although this may still be useful in instances when valve po-
sitioning is challenging (e.g., horizontal aorta).
Fig. 2.  Implantation of the more commonly used TAVI 
prostheses.
Initial position of the balloon-expandable Edwards SAPIEN 3 
valve (A), deployment (B) and final appearance (C). Initial position 
of the self-expanding Medtronic Evolut R valve (D), deployment (E) 
and final appearance (F). Appearance of the mechanically deployed 
Boston Scientific Lotus valve (G), deployment (H)  
and final appearance (I).
The goal is to achieve a reduction of the transvalvular 
aortic gradient of approximately 50% (if possible, less than 
25 mm Hg) and an increase of the aortic surface of 100% 
(example: 0.5 to 1 cm²). 
If the result is insufficient, a larger diameter balloon 
catheter is used. At the end of the procedure, arterial vas-
cular hemostasis is provided by a percutaneous Angio-Seal 
8-Fr (Terumo) or Proglide (Abbott) arterial closure system. 
The patient can usually leave the hospital the day after the 
procedure [32].
Current indications of TAVI
Aortic valve replacement surgery has been the standard 
treatment for many patients with aortic stenosis for many 
years and provides symptomatic relief and increased sur-
vival. Over the past 15 years, more than 400.000 percutane-
ous aortic valve implantations have been performed in more 
than 75 countries. The TAVI technique has now reached 
maturity, the intervention being standardized and the re-
sults predictable.
In high risk patients
According to European (2012) and North American 
(2014) recommendations, TAVI is currently indicated in in-
operable patients or is considered an alternative to surgery 
in high-risk patients [6, 33-36].
These indications are based on the results of the PART-
NER 1 studies with balloon deployed valves (Sapien, Ed-
wards Lifesciences) and the US CoreValve study with self-
expanding valves (CoreValve, Medtronic). The PARTNER 
1B study, published in 2010, randomized 358 patients, with 
tight RA and considered inoperable, between a transfemo-
ral TAVI with the 1st generation Sapien valve and medi-
cal treatment. The primary outcome (death) at 1 year was 
30.7% in the TAVI group and 50.7% in the medical group 
(p <0.001). The PARTNER 1A study, published in 2011, is 
a randomized non-inferiority study comparing in 699 pa-
tients with tight RA and considered to be at high risk for 
TAVI transfemoral (2/3 of patients) or transapical with 
valve 1st generation Sapien and AVR. The primary outcome 
(death) at 1 year was 24.2% in the TAVI group and 26.8% in 
the AVR group (p = 0.62). Therefore, the PARTNER study 
had indeed shown that in nonoperable patients with severe 
aortic stenosis, a TAVI significantly reduced mortality at 
one year compared to drug treatment3 and that in patients 
at very high risk of surgery. TAVI and conventional surgi-
cal replacement had a mortality rate comparable to one year 
[37, 38]. 
In 2014, another study conducted with the 1st genera-
tion CoreValve valve was also published. This study com-
pared TAVI and surgical therapy in 795 patients with aortic 
stenosis and considered at high surgical risk. The primary 
outcome (death) at 1 year was 14.2% in the TAVI group and 
19.1% in the AVR group (p = 0.04) [39] (fig. 3).
Fig. 3.  The TAVI devices.
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The results of these pivotal studies have therefore al-
lowed the entry of TAVI into the European recommenda-
tions for the management of patients with aortic stenosis 
(2012). TAVI is limited to inoperable patients and is consid-
ered an alternative to surgery in high-risk patients. Patients 
must have a life expectancy greater than 1 year, procedures 
must be validated by a medical-surgical meeting (Heart 
Team) and performed in experienced centers with on-site 
cardiac surgery [40-42].
Scores to predict surgical risk
The operative risk of aortic valve replacement (AVR) in 
a patient with severe aortic stenosis  is usually assessed by 
risk scores.
In Europe, the most used score is the recently updated 
EuroSCORE (European System for Cardiac Operative Risk 
Evaluation) in the form of EuroSCORE2, while in the Unit-
ed States, the most commonly used score is STS ( Society of 
Thoracic Surgeons score). The validity of these risk scores 
is usually assessed by their calibration (ratio of observed 
mortality to expected mortality) and their performance 
(area under the ROC curve). The first-generation logistics 
EuroSCORE is poorly calibrated (because it overestimates 
mortality) and the area under the ROC curve (0.62) is im-
perfect to discriminate at-risk patients. On the other hand, 
the EuroSCORE 2 and the STS are better calibrated (ratio 
between the observed mortality and the expected mortality 
close to 1) and more discriminating (area under the ROC 
curve between 0.73 and 0.75) [43-48].
EuroSCORE 2 and STS are scores to assess the risk of 
cardiac surgery before surgery, and the expected mortality 
in this type of patient. The higher the score, the higher the 
risk.
Patients whose EuroSCORE2 or STS score is >8% are 
considered at high risk and those for whom these scores are 
<4%, are at low risk.
Patients are usually considered to be at intermediate risk 
when the EuroSCORE2 or STS score is between 4 and 8% 
(This means that the risk of death expected at 30 days in case 
of RVA is between 4 and 8%).
These risk scores have many limitations because they do 
not take into account a certain number of cardiac or extra-
cardiac co-morbidities that will also impact on the operative 
risk. Patients with a porcelain aorta (massive circumferen-
tial calcification of the ascending aorta), regardless of the 
level of risk, are usually excluded from surgery because it 
is impossible to perform aortic clamping during the proce-
dure.
In addition, patients with a hostile chest due to defor-
mities or a history of radiotherapy are also usually consid-
ered by surgeons as high-risk patients. Some extracardiac 
comorbidities, such as advanced hepatic cirrhosis and se-
vere chronic respiratory insufficiency are also not taken 
into account. Finally, the fragility, autonomy, and cognitive 
functions of the patient, well known to geriatricians, are not 
taken into account by these risk scores even though it has 
been well demonstrated that they have a major impact on 
morbidity-operative mortality.
Outcomes in intermediate risk patients
Interestingly, the PARTNER 2 study included patients 
with a low STS score (5.8%) thus presenting a surgical risk 
this time intermediate. In this study, patients with severe 
aortic stenosis had comparable mortality or stroke rates af-
ter two years, regardless of technique. 
 However, comparing only those patients who received 
TAVI transfemoral to surgical patients, the two-year mor-
tality was significantly lower in the TAVI arm (p = 0.05). 
These results were confirmed in 2017 by the SURTAVI study, 
which also included patients at intermediate risk (STS score 
4.5%) and in which TAVI and conventional surgery were 
equal to two years in terms of mortality and stroke [49-51].
Three major studies have been reported in patients with 
tight RA and lower surgical risk. The first study (NOTION), 
conducted in Denmark and Sweden, involved a reduced 
population of 280 patients (70 years old), regardless of the 
level of surgical risk. Patients were randomized for TAVI 
with a CoreValve valve or surgery. The primary endpoint at 
1 year (associating death, heart attack and stroke) was simi-
lar in both groups (13.1% vs. 16.3%; p - 0.43).
The second study was conducted with the 2nd genera-
tion Sapien valve (model XT, PARTNER 2) and was pub-
lished in 2016. This study randomized 2032 patients, con-
sidered intermediate risk, between TAVI and conventional 
surgery. The primary endpoint for 2-year judgment (com-
bining death and stroke) was similar in the two groups 
(19.3% vs. 23.1%; p - 0.25) in the whole group studied. In 
contrast, the occurrence of death or stroke was significantly 
lower in the transfemoral TAVI group compared to surgery 
(16.8% vs. 20.4%; p - 0.05).
The latest study involves the 3rd generation Sapien valve 
(Sapien 3). This valve has the peculiarity of having an exter-
nal shell in its ring portion to greatly reduce the incidence 
of paravalvular leaks. In addition, the size of the catheter al-
lowing implantation has been significantly reduced to 14-16 
F, reducing vascular complications. This is a registry com-
paring 1.077 intermediate-risk patients treated with TAVI 
and 944 patients treated with RVA paired with the surgi-
cal cohort of the PARTNER 2 study. The primary endpoint 
(combining death, stroke) at 1 year was significantly lower 
in patients treated with TAVI (10.8% vs. 18.8%; p - 0.001) 
[52].
Thus, between 2012 and 2017, large randomized studies 
have demonstrated the value of TAVI in intermediate-risk 
patients, so it is logical that the number of TAVIs doubled 
between 2012 and 2015,  essentially, since the reimburse-
ment of TAVI by Social Security [53] (fig. 4). 
Taking these recent studies into account, the new rec-
ommendations of the European Society of Cardiology, pub-
lished in 2017, have evolved quite a bit in favor of TAVI. 
These are patients with a risk score (EuroSCORE 2 or STS 
score) of between 4 and 8%. These new recommendations 
include promoting the TAVI approach to any intermediate-
risk patient 75 years of age or older.
Finally, various studies are currently looking at TAVI 
in low-risk patients. The NOTION study (280 low-risk pa-
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tients), whose results at five years have just been presented, 
thus observed a similar mortality between the two strate-
gies. New data specific to patients at low risk of surgery is 
therefore to be expected soon [54-56].
For low risk patients (EuroSCORE 2 or STS score – 4%), 
but with other risk factors for conventional surgery such as 
significant fragility, aorta “porcelain” or radiation sequelae, 
different criteria should be taken into account when choos-
ing between conventional surgery or TAVI during a Heart 
Team were listed (tab. 1).
In addition, it is important to know the theoretical life 
expectancy of patients according to their age before making 
a choice between a TAVI and an SAVR (tab. 1).
Evolution of anesthesia
Historically, local anesthesia with conscious sedation 
had been used during the very first TAVI in 2002 but, at 
present, practices depend mainly on the experience and 
habits of the medical hospitals.
General anaesthesia (GA) is required for surgical access 
sites (e.g., transapical or transaortic). However, improve-
ments in pre-procedural assessment (particularly using 
advanced imaging of the aorta and peripheral vasculature 
using computed tomography and echocardiography) and 
engineering advances in prosthesis delivery systems (e.g. 
smaller delivery sheaths) have enabled the increasing use of 
conscious sedation and local/regional anaesthesia. Whilst 
no randomized studies have been conducted to ascertain 
if these are superior to GA, the advantages include shorter 
procedure times, the elimination of risks associated with 
GA and faster patient recovery [57, 58]. However, due to 
the better profile of the equipment and the ever-increasing 
experience of the different teams, local anesthesia is increas-
ingly used during the TAVI and convincing data support 
feasibility and safety. In terms of differences in prognosis 
between these two approaches, the data is still unclear. Sys-
tematic reviews of the literature and meta-analyses did not 
observe differences in mortality or stroke incidents, but two 
more recent studies, based on records of 1737 and 16543 
patients, suggest that local anesthesia with conscious seda-
tion may be associated with lower hospital mortality [59].
Fig. 4.  The decrease in the number of surgical aortic 
valvuloplasties performed at the University Hospital in Rouen, 
France, since the TAVI reimbursement in 2010.
Table 1
Aspects to be considered by the Heart Team for the 
decision between SAVR and TAVI in patients at 
increased surgical risk
CABG – coronary artery bypass grafting; CAD – coronary artery disease; 
EuroSCORE – European System for Cardiac Operative Risk Evaluation; 
LV – left ventricle; SAVR – surgical aortic valve replacement; STS – Society 
of Thoracic Surgeons; TAVI – transcatheter aortic valve implantation.
ReVIeW ARtIcLes O. Calenici. Moldovan Medical Journal. March 2020;63(1):44-51
TAVI for the treatment of aortic bioprosthesis degen-
erations
The new 2017 recommendations also enthrone TAVI as 
a therapeutic modality for the treatment of aortic biopros-
thesis degeneration. Aortic replacement with bioprosthe-
sis, about one in two patients will have degeneration with 
a necessary surgical reintervention rate in 10-30% of cases. 
As patients with aortic bioprosthesis degeneration are gen-
erally frail, elderly and that, by definition, they have a his-
tory of heart surgery, a percutaneous approach by a TAVI 
called valve-in-valve is at first sight attractive. Since the first 
case described in 2007, this procedure has been increasingly 
used in inoperable or very high-risk surgical patients with 
encouraging results. In the largest international registry of 
patients with aortic bioprosthesis degeneration at very high 
surgical risk, the one-year survival rate after a TAVI valve-
in-valve is indeed greater than 80%. This new indication to 
achieve a TAVI is now recognized in the guidelines of the 
European Society of Cardiology for inoperable or consid-
ered to be at high risk of surgical re-intervention. However, 
because the TAVI valve-in-valve situation is more complex 
than the management of a conventional aortic stenosis, it 
needs, more than ever, to be the subject of a multidisci-
plinary discussion within the Heart Team [60-64].
Futility of TAVI?
The identification of patients in whom a TAVI may be 
futile also remains an open question in 2018. Classically, fu-
tility is defined as a death or lack of functional improvement 
in the short term (6 to 12 months). The potential futility of 
TAVI is mainly evoked in patients with extreme fragility, 
chronic renal failure or chronic obstructive pulmonary dis-
ease (COPD). In a study based on more than 300 consecu-
tive patients, about one-third of whom had COPD, was ob-
served that a TAVI had proved futile in more than one third 
of the cases. This excess mortality was also observed in oth-
er studies. The full clinical control is expected to help Heart 
Team members distinguish patients for whom symptomatic 
benefit is expected from patients for whom the intervention 
will not improve quality of life or independence. Pragmati-
cally however, Mok et al. propose performing a six-minute 
walk test and identify a distance of less than 170 meters as a 
good predictor of futility [65, 66].
Heart team
Finally, remember that according to the new recom-
mendations, to define in a personalized way the most ap-
propriate treatment for a patient, each case must be assessed 
in a multidisciplinary way by specialists, the Heart Team, 
already mentioned several times in this article. If the con-
cept was developed long ago in the treatment of coronary 
heart disease, its use for the treatment of valvulopathies is 
recent and follows the advent of percutaneous therapeu-
tic approaches. According to the European recommenda-
tions, this Heart Team brings together a panel of specialists, 
such as a cardiac surgeon, an interventional cardiologist, a 
non-invasive cardiologist, imaging specialist, a radiologist, 
a cardiac anesthesiologist and a geriatrician to be able to 
establish an individualized therapeutic project, taking into 
account all the dimensions (anatomical, functional and hu-
man) of the pathology of the patient with the ultimate goal 
of establishing if the patient is a candidate for a conventional 
surgical treatment or if his case is more a transcatheter or 
medical approach.
Conclusions
1. There is no doubt that TAVI is superior to medical 
treatment in inoperable patients.
2. In operable patients, TAVI is not inferior to surgery 
in high-risk patients and in intermediate-risk patients and 
even superior to surgery when a transfemoral route is fea-
sible.
3. It is also important to consider comorbidities not tak-
en into account by their risk scores and geriatric status in 
order to make the best decision for our patients.
4. The extension of indications to low-risk patients is al-
ready being evaluated (“PARTNER 3” and “CoreValve low 
risk” studies) and the results are expected in 2019-2020.
5. In parallel, it is important to collect as much infor-
mation as possible about the durability of percutaneously 
implanted bioprostheses.
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